Current Report Filing (8-k)
February 07 2022 - 4:01PM
Edgar (US Regulatory)
0001325618
false
0001325618
2022-02-07
2022-02-07
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM 8-K
CURRENT
REPORT Pursuant
to
Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of report (Date of earliest
event reported): February 7, 2022
Iradimed Corporation
(Exact name of registrant as specified
in its charter)
Delaware
(State
or other jurisdiction of incorporation)
001-36534
|
|
73-1408526
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
1025 Willa Springs Dr., Winter Springs, FL
|
|
32708
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(407) 677-8022
(Registrant’s
telephone number, including area code)
(Former name or former address, if changed
since last report)
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class:
|
|
Trading Symbol
|
|
Name of each exchange on which registered:
|
Common stock, par value $0.0001
|
|
IRMD
|
|
NASDAQ Capital Market
|
On February 5, 2022, the Board of Directors of
iRadimed Corporation declared a special cash dividend of $1.00 per share on the Company’s
outstanding common stock. The special cash dividend is payable on February 24, 2022, to shareholders of record at the close of business
on February 17, 2022. A copy of the press release is attached hereto as Exhibit 99.1.
The information in this Item 8.01, including Exhibit
99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”) or otherwise subject to the liabilities of that Section. Furthermore, such information, including Exhibit 99.1, shall
not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly
set forth by specific reference in such a filing.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
IRADIMED CORPORATION
|
|
|
|
Date: February 7, 2022
|
|
|
|
|
|
|
By:
|
/s/Chris Scott
|
|
Name:
|
Chris Scott
|
|
Title:
|
Chief Financial and Operating Officer
|
iRadimed (NASDAQ:IRMD)
Historical Stock Chart
From May 2024 to Jun 2024
iRadimed (NASDAQ:IRMD)
Historical Stock Chart
From Jun 2023 to Jun 2024